Anti-Coagulants - NAFTA

NAFTA

Highlights

The Anti-Coagulants market in NAFTA is projected to reach a revenue of US$17.56bn by 2024.
This market is expected to exhibit a compound annual growth rate (CAGR 2024-2029) of 5.61%, leading to a market volume of US$23.07bn by 2029.
When compared globally, United States is anticipated to generate the highest revenue in this market, with US$16.74bn projected for 2024.
The United States is experiencing a surge in demand for novel oral anticoagulants, driven by an aging population and increasing prevalence of cardiovascular diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Coagulants market in NAFTA has been experiencing significant growth in recent years due to a number of factors.

Customer preferences: One of the key drivers of growth in the Anti-Coagulants market in NAFTA is changing customer preferences. As the population ages, there is a growing demand for treatments to prevent and manage a range of medical conditions, including heart disease and stroke. Anti-Coagulants are increasingly being used as a preventative measure for these conditions, as well as for the treatment of other conditions such as deep vein thrombosis and pulmonary embolism.

Trends in the market: There are several trends in the Anti-Coagulants market in NAFTA that are contributing to its growth. One of the most significant is the shift towards newer, more advanced drugs. These drugs are more effective and have fewer side effects than older medications, making them more appealing to both patients and healthcare providers.Another trend in the market is the increasing use of combination therapies. This involves combining different types of Anti-Coagulants to achieve better results. For example, some patients may be prescribed a combination of Anti-Coagulants and antiplatelet drugs to reduce the risk of blood clots and stroke.

Local special circumstances: The Anti-Coagulants market in NAFTA is also influenced by a number of local special circumstances. For example, the high prevalence of heart disease and stroke in the United States and Canada has led to a greater demand for Anti-Coagulants in these countries. In addition, the high cost of healthcare in the United States has made it difficult for many patients to access the treatments they need, leading to a greater reliance on generic Anti-Coagulants.

Underlying macroeconomic factors: Finally, there are several underlying macroeconomic factors that are contributing to the growth of the Anti-Coagulants market in NAFTA. One of the most significant is the aging population. As the baby boomer generation continues to age, there is a growing demand for healthcare services and treatments. In addition, advances in medical technology and research are leading to the development of new and more effective Anti-Coagulants, further driving growth in the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.